Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab in locally advanced rectal cancer
NCT07917468Phase 3Not yet recruiting
- Sponsor
- Innovent Biologics
- Start
- Nov 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in rectal cancer, sponsored by Innovent Biologics. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07917468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917468.